文献速递类风湿关节炎

类风湿关节炎患者接受利妥昔单抗治疗的感染发生率、时间及剂量依赖性:一项回顾性队列研究

Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该回顾性队列研究纳入2012至2021年在Sint Maartenskliniek接受利妥昔单抗(RTX)1000、500或200 mg/周期治疗的490例类风湿关节炎(RA)患者,共识别1254患者年中的819例感染。200、500、1000 mg组感染发生率分别为每100患者年41、54、71例;200 mg组较1000 mg组校正IRR为0.35(95%CI 0.17, 0.72,P=0.004)。接受1000或500 mg的患者中,感染似在输注后前两个月更频繁,提示与峰浓度相关。

要点

  • 200 mg超低剂量RTX组感染发生率低于1000 mg组,校正IRR 0.35(95%CI 0.17, 0.72,P=0.004)。
  • 接受1000或500 mg RTX的患者中,感染似在输注后前两个月更频繁,提示与峰浓度相关。
  • 大多数感染为轻度,呼吸道感染最常见。

核心结论

  • 超低剂量(200 mg)RTX与RA患者较低的感染风险相关。
  • 作者认为,未来聚焦超低剂量和RTX缓慢释放(如通过皮下给药)的干预可能降低感染风险。

研究设计与样本

  • 回顾性队列研究,纳入2012至2021年在Sint Maartenskliniek接受每周期1000、500或200 mg RTX治疗的RA患者。
  • 从电子健康记录中提取患者、疾病、治疗和感染特征,使用混合效应泊松回归分析感染发生率及与RTX输注的剂量和时间关系。

主要发现

  • 在490例患者中,1254患者年内共识别819例感染。
  • 大多数感染为轻度,呼吸道感染最常见。
  • 200、500、1000 mg组的感染发生率分别为每100患者年41、54、71例。
  • 200 mg组较1000 mg组感染发生率显著更低,校正IRR为0.35(95%CI 0.17, 0.72,P=0.004)。
  • 在接受1000或500 mg RTX的患者中,感染似在输注后前两个月较治疗周期后期更频繁,提示与峰浓度相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Rituximab (RTX) is a safe and effective treatment for RA. However, there are some concerns about infection risk and preliminary data suggest dose and time dependency. This study aims to determine the infection incidence in a large real-life population of RA patients using RTX, with special focus on (ultra-)low dosing and time since last infusion. METHODS: RA patients treated with 1000, 500 or 200 mg RTX per cycle between 2012 and 2021 at the Sint Maartenskliniek were included in a retrospective cohort study. Patient-, disease-, treatment- and infection characteristics were retrieved from electronic health records. Infection incidence rates, dose and time relations with RTX infusion were analysed using mixed-effects Poisson regression. RESULTS: Among 490 patients, we identified 819 infections in 1254 patient years. Most infections were mild and respiratory tract infections were most common. Infection incidence rates were 41, 54 and 71 per 100 patient years for doses of 200, 500 and 1000 mg. Incidence rate ratio (IRR) was significantly lower for 200 mg compared with 1000 mg (adjusted IRR 0.35, 95% CI 0.17, 0.72, P = 0.004). In patients receiving 1000 or 500 mg RTX, infections seemed to occur more frequently within the first two months after infusion compared with later on in the treatment cycle, suggesting an association with peak concentration. CONCLUSION: Ultra-low dosing (200 mg) of RTX is associated with a lower risk of infections in RA. Future interventions focusing on ultra-low dosing and slow release of RTX (e.g. by subcutaneous administration) may lower infection risk.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Veeken LD, Opdam MAA, Verhoef LM, et al. Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study. Rheumatology (Oxford). 2024. PMID: 37410085. doi:10.1093/rheumatology/kead328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。